CL2015000119A1 - El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera. - Google Patents
El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera.Info
- Publication number
- CL2015000119A1 CL2015000119A1 CL2015000119A CL2015000119A CL2015000119A1 CL 2015000119 A1 CL2015000119 A1 CL 2015000119A1 CL 2015000119 A CL2015000119 A CL 2015000119A CL 2015000119 A CL2015000119 A CL 2015000119A CL 2015000119 A1 CL2015000119 A1 CL 2015000119A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- epoc
- carbonitrile
- propan
- trifluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261672455P | 2012-07-17 | 2012-07-17 | |
US201361748874P | 2013-01-04 | 2013-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000119A1 true CL2015000119A1 (es) | 2015-04-24 |
Family
ID=49117887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000119A CL2015000119A1 (es) | 2012-07-17 | 2015-01-16 | El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera. |
Country Status (39)
Country | Link |
---|---|
US (5) | US8957104B2 (es) |
EP (1) | EP2875013B1 (es) |
JP (1) | JP6106746B2 (es) |
KR (1) | KR102127939B1 (es) |
CN (1) | CN104619693B (es) |
AR (1) | AR091770A1 (es) |
AU (1) | AU2013291721B2 (es) |
BR (1) | BR112015000940B1 (es) |
CA (1) | CA2879104C (es) |
CL (1) | CL2015000119A1 (es) |
CO (1) | CO7240378A2 (es) |
CR (1) | CR20150008A (es) |
CY (1) | CY1120064T1 (es) |
DK (1) | DK2875013T3 (es) |
DO (1) | DOP2015000004A (es) |
EA (1) | EA026371B8 (es) |
ES (1) | ES2657912T3 (es) |
HK (1) | HK1208867A1 (es) |
HR (1) | HRP20180061T1 (es) |
HU (1) | HUE036238T2 (es) |
IL (1) | IL236448A (es) |
IN (1) | IN2014KN02993A (es) |
JO (1) | JO3384B1 (es) |
LT (1) | LT2875013T (es) |
ME (1) | ME02996B (es) |
MX (1) | MX349943B (es) |
MY (2) | MY198512A (es) |
NZ (1) | NZ703129A (es) |
PE (1) | PE20150371A1 (es) |
PH (1) | PH12015500104B1 (es) |
PL (1) | PL2875013T3 (es) |
PT (1) | PT2875013T (es) |
RS (1) | RS56810B1 (es) |
SG (1) | SG11201408493WA (es) |
SI (1) | SI2875013T1 (es) |
TW (1) | TWI574946B (es) |
UY (1) | UY34911A (es) |
WO (1) | WO2014013309A1 (es) |
ZA (1) | ZA201500096B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
CA2879104C (en) * | 2012-07-17 | 2020-08-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Indolecarbonitriles as selective androgen receptor modulators |
US9902694B2 (en) * | 2014-01-21 | 2018-02-27 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Crystalline forms |
KR20190077607A (ko) * | 2014-10-16 | 2019-07-03 | 지티엑스, 인코포레이티드 | Sarm을 이용하는 비뇨기 장애의 치료 방법 |
CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
CN110437125B (zh) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | 一种Tezacaftor中间体II的制备方法 |
WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
CN115010574B (zh) * | 2022-06-06 | 2024-01-05 | 爱斯特(成都)生物制药股份有限公司 | 1-溴-2-氯-4-氟-2碘苯的合成方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9908280A (pt) | 1998-02-25 | 2000-10-31 | Genetics Inst | Inibidores de enzimas de fosfolipase |
EP1087970B1 (en) * | 1998-06-19 | 2004-04-28 | Pfizer Products Inc. | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
WO2003099777A1 (en) | 2002-05-24 | 2003-12-04 | Bayer Cropscience Ag | Process for the preparation of thioalkylamine derivatives |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
CN1960973A (zh) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物 |
JP5070041B2 (ja) | 2004-05-03 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドローゲン受容体モジュレーター(sarms)としての新規インドール化合物 |
CA2565205A1 (en) | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
US7282507B2 (en) | 2004-05-03 | 2007-10-16 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
WO2005118539A1 (en) * | 2004-06-01 | 2005-12-15 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
ATE540952T1 (de) * | 2005-07-29 | 2012-01-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese |
GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
CN101426778A (zh) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | 作为组胺-3拮抗剂的n-经取代-氮杂环基胺 |
WO2008042571A2 (en) * | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
AU2010308028A1 (en) * | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
ES2461967T3 (es) * | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
AU2011274787B2 (en) | 2010-07-07 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
CN103384661B (zh) | 2011-01-20 | 2016-08-10 | 默沙东公司 | 盐皮质激素受体拮抗剂 |
CN103415520B8 (zh) * | 2011-12-21 | 2017-04-05 | 江苏恒瑞医药股份有限公司 | 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用 |
CA2879104C (en) | 2012-07-17 | 2020-08-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Indolecarbonitriles as selective androgen receptor modulators |
US9902694B2 (en) * | 2014-01-21 | 2018-02-27 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Crystalline forms |
-
2013
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/lt unknown
- 2013-07-15 MX MX2015000825A patent/MX349943B/es active IP Right Grant
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 EA EA201492237A patent/EA026371B8/ru not_active IP Right Cessation
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 AR ARP130102513A patent/AR091770A1/es active IP Right Grant
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/pt active IP Right Grant
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/zh active Active
- 2013-07-15 RS RS20180119A patent/RS56810B1/sr unknown
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 UY UY0001034911A patent/UY34911A/es not_active Application Discontinuation
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/es active IP Right Grant
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/hu unknown
- 2013-07-15 PT PT137589750T patent/PT2875013T/pt unknown
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/ko active IP Right Grant
- 2013-07-15 PL PL13758975T patent/PL2875013T3/pl unknown
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/ar active
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 TW TW102125297A patent/TWI574946B/zh active
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en active Application Filing
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/ja active Active
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/me unknown
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/es active Active
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/es unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/es unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/es unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104B1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/es unknown
- 2015-09-30 HK HK15109640.8A patent/HK1208867A1/xx unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-01-15 HR HRP20180061TT patent/HRP20180061T1/hr unknown
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/el unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000119A1 (es) | El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera. | |
AU2018260808A1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
CL2012002037A1 (es) | Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca | |
CL2008002110A1 (es) | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus. | |
BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
CL2013003816A1 (es) | Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades. | |
BRPI0909179A2 (pt) | Composição farmacêutica, e, método de tratamento de uma doença autoimune. | |
EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
MX2015011509A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
CL2009001248A1 (es) | Compuestos derivados de indazolilo sustituido con fenilo, que actúan como moduladores de glucocorticoides; composición y combinación farmacéutica que comprenden a uno de los compuestos; y uso de los compuestos en la preparación de medicamentos para el tratamiento de enfermedades inflamatorias y respiratorias. | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
BR112013009970A2 (pt) | método para determinar uma característica do ritmo circadiano de um paciente. | |
EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение |